Protecting vision after eye or brain injuries and in a hereditary retinal condition

BLRD Research Career Scientist Award Application

NIH-funded research VA Western New York Healthcare System · NIH-11212745

Working to find drug treatments that protect or slow vision loss after traumatic eye or brain injuries and in a genetic form of retinitis pigmentosa (RP59).

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionVA Western New York Healthcare System NIH-funded
Lab location1 site (Buffalo, United States)
Project IDNIH-11212745 on NIH RePORTER

What this research studies

My lab studies how cholesterol-related molecules keep the retina healthy and how those processes go wrong after trauma or in a hereditary retinal disease called RP59. We use laboratory and preclinical models that mimic eye and blast-related brain injuries and genetic forms of retinal degeneration to trace the molecular and cellular changes that cause vision loss. The work aims to identify practical pharmacological interventions that could prevent or slow this damage. Research is conducted at the VA Western New York Healthcare System and builds on ongoing VA-funded projects toward treatments that could move into clinical testing.

Who could benefit from this research

Good fit: Ideal candidates would include veterans or others with recent traumatic eye or TBI-related visual problems and people diagnosed with the hereditary retinal condition RP59 who want to consider future treatment trials.

Not a fit: People whose vision loss stems from unrelated eye diseases or long-standing, irreversible blindness are unlikely to receive direct benefit from this project.

Why it matters

Potential benefit: If successful, this research could lead to medicines that prevent or slow vision loss from battlefield or other traumatic eye/brain injuries and from some inherited retinal disorders.

How similar studies have performed: Related preclinical studies have identified promising targets for retinal protection, but proven patient treatments for trauma-induced vision loss and RP59 remain limited and under development.

Where this research is happening

Buffalo, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.